Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
Melinta Retains Rights to Commercialize Delafloxacin as Baxdela in the US
Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced the signing of a development and commercialization agreement. As part of this agreement, Melinta has granted the Menarini Group exclusive rights to commercialize Delafloxacin (known as Baxdela in the US), an investigational anionic fluoroquinolone, under their own brands in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia (Japan excluded), and the Commonwealth of Independent States (CIS) including Russia. Under the terms of the collaboration, Melinta will be receiving an upfront payment and near-term development and regulatory milestone payments, as well as sales milestones and royalties from Menarini Group.